Bevurogant

DB21507ExperimentalSmall molecule

Bevurogant is a small molecule drug. The usage of the INN stem '-rogant' in the name indicates that Bevurogant is a retinoic acid receptor-related orphan receptor gamma (RORY) antagonist and... Bevurogant has a monoisotopic molecular weight of 532.2 Da.

Mechanism: Pharmacologically active on Nuclear receptor ROR-gamma
Curator reviewed
Formula / weight: C₂₆H₂₈N₈O₃S · 532.62 g/mol (avg)

Resolves to

Compound

UNII1874HVK11ICAS1817773-66-2ChEMBLCHEMBL4760304

Structure

InChIKeyHVVHIBHBDCYLDI-HNNXBMFYSA-NSMILESC[C@@H](C1CC1)N1C(=O)C(NCC2=NC=C(C=C2)S(C)(=O)=O)=NC2=CN=C(N=C12)C1=C(N=CN=C1C)C1CC1

Targets

P51449RORC

What you can answer from here — as of August 31, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Bevurogant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account